Argus analyst David Toung raised the firm’s price target on Labcorp (LH) to $290 from $260 and keeps a Buy rating on the shares after its Q4 ...

Labcorp Holdings Inc. LH, or Labcorp, is prioritizing key specialty testing areas, such as oncology, women’s health, autoimmune disease and neurology, aiming to tap into strong growth opportunities.

Citi upgraded Charles River Laboratories (NYSE:CRL) and LabCorp (NYSE:LH) while downgrading Quest Diagnostics (NYSE:DGX), ...

Citi upgraded Labcorp (LH) to Buy from Neutral with a price target of $300, up from $250. Utilization rates have been running high ...

Labcorp has been a great trade, beating the S&P 500 by 6.9%. Its stock price has climbed to $255.01, representing a healthy ...

A Durham company with a slumping stock is implementing changes to its board after reaching a deal with an activist investor.

Shares of Labcorp Holdings Inc. LH rose 1.09% to $256.81 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 1.22% to 5,778.15 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Shares of Labcorp Holdings Inc. LH rose 1.31% to $251.04 Friday, on what proved to be an all-around positive trading session ...

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the clinical availability of Labcorp® Plasma CompleteTM, a circulating tumor DNA (ctDNA)-based ...

The board of Labcorp Holdings Inc. ( NYSE:LH ) has announced that it will pay a dividend of $0.72 per share on the ...

Labcorp Holdings Inc. LH, or Labcorp, is prioritizing key specialty testing areas, such as oncology, women’s health, autoimmune disease and neurology, aiming to tap into strong growth opportunities.